The United Kingdom and the United States have established a important commercial pact that will preserve no duties on UK drug shipments being sold in the American market.
Key Provisions of the Accord
As part of the deal, the UK has committed to increase funding on drugs through the National Health Service (NHS). This commitment ensures that tariffs on these vital goods will remain at zero for a duration of the next three years.
This agreement comes after earlier threats to dramatically increase tariffs on branded pharmaceutical products, with increases discussed up to double the cost.
"This agreement between the United Kingdom bolsters the global environment for new treatments and introduces long-overdue fairness to transatlantic medicine commerce," a statement noted.
Trade Significance
Drugs constitute one of the the United Kingdom's largest goods shipped to the United States, which is by far the primary market for major companies like GSK and AstraZeneca.
Statistics show that in the 12 months to the end of last September, the UK shipped drugs worth billions to the US. This amount accounted for 17.4% of British export trade in that period.
"This deal secures employment, boosts capital expenditure and sets the stage for the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary commented.
Specific British Pledges
The deal entails several notable commitments from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to increase overall NHS spending on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Payback Limit: The percentage manufacturers must pay back to the NHS to prevent overspending will be limited at 15%. Previously, refunds were more than 20%.
Industry Background
This agreement takes place against a ongoing dispute between the pharmaceutical industry and the UK government over spending levels and regulatory access.
The disagreement were exacerbated by assertions that American customers were charged significantly more for the equivalent treatments than patients in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been delayed or cancelled, while major expansions have been announced toward US facilities.
A senior figure publicly accepted that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had shrunk as a share of its resources over the previous ten-year period.